Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: Comparative safety profiles of newer agents

Kevin Kelly, Ronan T Swords, Devalingam Mahalingam, Francis J. Giles

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Imatinib is broadly used in the frontline treatment of chronic myeloid leukemia (CML). Although long-term safety and efficacy have been established, some patients will not respond to imatinib. Nilotinib and dasatinib successfully recapture responses for most patients with imatinib-refractory or -intolerant disease. These drugs have different safety profiles, which are likely associated with their divergent inhibitory targets. The presence of BcrAbl mutations and safety profiles of available therapies in relation to patient history should be considered when choosing a second-line agent. This review evaluates the safety and tolerability of agents approved for CML treatment and briefly discusses newer third-line agents.

Original languageEnglish
Pages (from-to)1399-1413
Number of pages15
JournalLeukemia and Lymphoma
Volume51
Issue number8
DOIs
StatePublished - Aug 1 2010
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Safety
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Therapeutics
Mutation
Pharmaceutical Preparations
Imatinib Mesylate

Keywords

  • chronic myeloid leukemia
  • dasatinib
  • Imatinib
  • nilotinib
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase : Comparative safety profiles of newer agents. / Kelly, Kevin; Swords, Ronan T; Mahalingam, Devalingam; Giles, Francis J.

In: Leukemia and Lymphoma, Vol. 51, No. 8, 01.08.2010, p. 1399-1413.

Research output: Contribution to journalArticle

Kelly, Kevin ; Swords, Ronan T ; Mahalingam, Devalingam ; Giles, Francis J. / Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase : Comparative safety profiles of newer agents. In: Leukemia and Lymphoma. 2010 ; Vol. 51, No. 8. pp. 1399-1413.
@article{9b07b626e94a4f1890597ebe3163148d,
title = "Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: Comparative safety profiles of newer agents",
abstract = "Imatinib is broadly used in the frontline treatment of chronic myeloid leukemia (CML). Although long-term safety and efficacy have been established, some patients will not respond to imatinib. Nilotinib and dasatinib successfully recapture responses for most patients with imatinib-refractory or -intolerant disease. These drugs have different safety profiles, which are likely associated with their divergent inhibitory targets. The presence of BcrAbl mutations and safety profiles of available therapies in relation to patient history should be considered when choosing a second-line agent. This review evaluates the safety and tolerability of agents approved for CML treatment and briefly discusses newer third-line agents.",
keywords = "chronic myeloid leukemia, dasatinib, Imatinib, nilotinib, tyrosine kinase inhibitor",
author = "Kevin Kelly and Swords, {Ronan T} and Devalingam Mahalingam and Giles, {Francis J.}",
year = "2010",
month = "8",
day = "1",
doi = "10.3109/10428194.2010.491135",
language = "English",
volume = "51",
pages = "1399--1413",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase

T2 - Comparative safety profiles of newer agents

AU - Kelly, Kevin

AU - Swords, Ronan T

AU - Mahalingam, Devalingam

AU - Giles, Francis J.

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Imatinib is broadly used in the frontline treatment of chronic myeloid leukemia (CML). Although long-term safety and efficacy have been established, some patients will not respond to imatinib. Nilotinib and dasatinib successfully recapture responses for most patients with imatinib-refractory or -intolerant disease. These drugs have different safety profiles, which are likely associated with their divergent inhibitory targets. The presence of BcrAbl mutations and safety profiles of available therapies in relation to patient history should be considered when choosing a second-line agent. This review evaluates the safety and tolerability of agents approved for CML treatment and briefly discusses newer third-line agents.

AB - Imatinib is broadly used in the frontline treatment of chronic myeloid leukemia (CML). Although long-term safety and efficacy have been established, some patients will not respond to imatinib. Nilotinib and dasatinib successfully recapture responses for most patients with imatinib-refractory or -intolerant disease. These drugs have different safety profiles, which are likely associated with their divergent inhibitory targets. The presence of BcrAbl mutations and safety profiles of available therapies in relation to patient history should be considered when choosing a second-line agent. This review evaluates the safety and tolerability of agents approved for CML treatment and briefly discusses newer third-line agents.

KW - chronic myeloid leukemia

KW - dasatinib

KW - Imatinib

KW - nilotinib

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=77955443343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955443343&partnerID=8YFLogxK

U2 - 10.3109/10428194.2010.491135

DO - 10.3109/10428194.2010.491135

M3 - Article

C2 - 20528247

AN - SCOPUS:77955443343

VL - 51

SP - 1399

EP - 1413

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 8

ER -